TROG Cancer Research
Members Login   CQMS Login

TROG 03.03 (HDNLHL4)

Primary sponsor: Australasian Leukaemia & Lymphoma Group (ALLG)
Collaborating group: TROG


Involved-Field Radiotherapy With Transplantation For Hodgkin’s Disease And Non-Hodgkin’s Lymphoma


Treatment options for patients with relapsed lymphoma include standard-dose chemotherapy, radiotherapy or high-dose chemotherapy and peripheral blood stem cell transplantation.

It has been found that if lymphoma recurs after transplantation it often does so in sites involved prior to transplantation. Radiotherapy can prevent some of these relapses, and may improve the overall results of transplantation. Radiotherapy is often given only to bulky sites (i.e. more than 5-10 cm in size) of lymphoma following transplantation, but the optimal dose and area of radiotherapy is not known. It is possible that treating all the areas of lymphoma (including non-bulky areas) may be more effective.

In this research study, radiotherapy was given to all the areas known to be affected by lymphoma (other than bone marrow) with the aims of assessing the ability of radiotherapy to reduce the risk of relapse following transplantation, and carefully evaluating the side effects of adding radiotherapy to transplantation.

Final accrual


Trial Status

Closed to Follow-up, December 2012

Trial chairperson

A/Prof Andrew Wirth
Peter MacCallum Cancer Centre 

Trial contact

Dr Bereha Khodr
Phone: 03 9656 1143

Further information

TROG 03.03 on Australian Cancer Trials website

Trial resources for TROG members

TROG 03.03 member page

We are thankful to our 14,500 patients who have participated in our research. Please continue the generous support.